



## ORIGINAL

# Assessment of adrenomedullin and proadrenomedullin as predictors of mortality in septic patients: A systematic review and meta-analysis



Q. Li<sup>1</sup>, B.S. Wang<sup>1</sup>, L. Yang, C. Peng, L.B. Ma, C. Chai\*

3rd Department of General Surgery, First Hospital of Lanzhou University, Lanzhou 730000, China

Received 11 August 2017; accepted 26 October 2017

### KEYWORDS

Adrenomedullin;  
Proadrenomedullin;  
Sepsis;  
Mortality

### Abstract

**Objective:** To ascertain the ability of adrenomedullin (ADM) and proadrenomedullin (proADM) to predict mortality in sepsis patients.

**Design:** A systematic literature search was made of the PubMed, EMBASE, Cochrane and China National Knowledge Infrastructure (CNKI) databases before May 2017, supplemented by manual searches of references. A meta-analysis of high-quality clinical studies was subsequently performed to assess the association between ADM/proADM and mortality risk among patients with sepsis.

**Patients:** Thirteen studies involving 2556 patients were included in the study.

**Interventions:** Two reviewers independently identified articles, extracted data, assessed quality and cross-checked the results. The predictive values of ADM and proADM referred to mortality were assessed by relative risk (RR). The overall diagnostic accuracy of ADM and proADM in application to sepsis was pooled according to a bivariate model. Publication bias was assessed using Deek's funnel plot asymmetry test.

**Results:** Elevated ADM or proADM levels were associated with increased mortality (pooled RR = 3.31; 95%CI 2.31–4.75). Subgroup analyses indicated the pooled RRs were 3.12 (95%CI 1.75–5.56) and 3.43 (95%CI 2.21–5.31) for ADM and proADM, respectively. The pooled sensitivity and specificity were 0.72 (95%CI 0.64–0.78) and 0.77 (95%CI 0.69–0.83), respectively. The overall area under the summary receiver operating characteristic (SROC) curve was 0.80 (95%CI 0.77–0.84). Publication bias was not statistically significant.

**Conclusions:** Both ADM and proADM might serve as useful markers for predicting the prognosis of sepsis.

© 2017 Elsevier España, S.L.U. y SEMICYUC. All rights reserved.

\* Corresponding author.

E-mail addresses: [chasechai@gmail.com](mailto:chasechai@gmail.com), [cd4971@163.com](mailto:cd4971@163.com) (C. Chai).

<sup>1</sup> Contributed equally.

**PALABRAS CLAVE**

Adrenomedulina;  
 Proadrenomedulina;  
 Sepsis;  
 Mortalidad

## Evaluación de adrenomedulina y proadrenomedulina como factores pronóstico de la mortalidad en pacientes sépticos: revisión sistemática y metaanálisis

**Resumen**

**Objetivo:** Establecer la capacidad de la adrenomedulina (ADM) y la proadrenomedulina (proADM) para predecir la mortalidad en pacientes sépticos.

**Diseño:** Se llevó a cabo una búsqueda sistemática de la literatura científica en las bases de datos PubMed, EMBASE, Cochrane y China National Knowledge Infrastructure (CNKI) antes de mayo de 2017, complementada con búsquedas manuales de referencia. Posteriormente, se realizó un metaanálisis de estudios clínicos de alta calidad para evaluar la asociación entre ADM/proADM y el riesgo de mortalidad en pacientes con sepsis.

**Pacientes:** En este análisis se incluyeron 30 estudios en los que participó un total de 2.556 pacientes.

**Intervenciones:** Dos revisores identificaron de forma independiente los artículos, extrajeron los datos, evaluaron la calidad y realizaron verificaciones cruzadas de los resultados. Se evaluó el valor de ADM y proADM como factor pronóstico de mortalidad a partir del riesgo relativo (RR). La precisión global del diagnóstico con ADM y proADM en pacientes con sepsis se agrupó utilizando un modelo de 2 variables. Se evaluó el sesgo de publicación utilizando una prueba de Deek para asimetría de gráfico en embudo.

**Resultados:** Las concentraciones elevadas de ADM o proADM se asociaron a un aumento de la mortalidad (RR agrupado: 3,31; IC del 95%: 2,31-4,75). Los análisis por subgrupos indicaron que los RR agrupados eran de 3,12 (IC del 95%: 1,75-5,56) y 3,43 (IC del 95%: 2,21-5,31) para ADM y proADM, respectivamente. La sensibilidad y especificidad agrupadas fueron 0,72 (IC del 95%: 0,64-0,78) y 0,77 (IC del 95%: 0,69-0,83), respectivamente. El área global bajo la curva (SROC) fue de 0,80 (IC del 95%: 0,77-0,84). El sesgo de publicación no fue estadísticamente relevante.

**Conclusiones:** Tanto ADM como proADM pueden ser marcadores útiles para predecir el pronóstico de pacientes con sepsis.

© 2017 Elsevier España, S.L.U. y SEMICYUC. Todos los derechos reservados.

**Introduction**

Sepsis, a syndrome with physiologic, pathologic, and biochemical abnormalities triggered by infection, is a major challenge in intensive care units (ICUs) and emergency departments (EDs).<sup>1</sup> Despite advances in antibiotic therapy and modern life support in past decade, the in-hospital mortality rate of US patients with sepsis has remained as high as 15%, posing a heavy burden to critically ill populations.<sup>2</sup>

One the most important reasons why first-line clinical physicians fail to provide timely and accurate treatment to sepsis patients is the lack of rapid and accurate diagnostic tools.<sup>3</sup> It is therefore necessary and urgent to develop a rapid, simple, and accurate method to improve the diagnosis of sepsis. Adrenomedullin (ADM) is a 52-amino-acid peptide which can act as a hormone and is produced and secreted by multiple mammalian tissues during physiologic and infectious stress.<sup>4</sup> Several clinical trials have demonstrated that ADM increases significantly in patients with sepsis and is positively associated with disease severity. Compared with normal individuals, ADM levels are 25- to 30-fold higher in patients with septic shock.<sup>5,6</sup> Thus, quantification of ADM may be helpful in diagnosing and monitoring sepsis as well as establishing prognosis.<sup>5</sup> As ADM is rapidly cleared from the circulation, the mid-region part of proadrenomedullin (proADM) that directly shows level of the fast degraded active peptide of ADM may be used instead of ADM as a predictor of sepsis.<sup>7</sup>

The present systematic review and meta-analysis aims to evaluate the prognostic value of ADM and proADM for mortality of patients with sepsis and assess their diagnostic accuracy.

**Methods****Search strategy**

This systematic review and meta-analysis was performed and reported in accordance with the guidelines of Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).<sup>8</sup> PubMed, EMBASE and The Cochrane Library were searched for trials in English, and China National Knowledge Infrastructure (CNKI) database were searched for trials in Chinese to identify the relevant published studies for clinical data. Searches were conducted separately for each literature databases up to May 2017. The search terms for each database were ("adrenomedullin" OR "proadrenomedullin" OR "mid-regional proadrenomedullin" OR "MR-proadrenomedullin") AND ("sepsis" OR "septicemia" OR "septicaemia" OR "septic" OR "septic shock"). In addition to our computerized search, the bibliographies of all articles were reviewed to look for other potential articles with eligible data for the meta-analysis. The corresponding authors or first authors of the publications were contacted if additional information

was needed, results were unclear, or relevant data were not reported.

Studies were considered eligible for the systematic review and meta-analysis if they fulfilled the following criteria: 1) data was from an original, peer-reviewed study rather than review articles or meeting abstracts; 2) patients with sepsis or septic shock; 3) studies that provided mortality or diagnostic characteristics, that is, the area under the receiver operating characteristic (ROC) curve (AUC), or sensitivity and specificity. We excluded studies that were animal studies or duplicate studies.

## Article screening

After deduplication, references were screened based on their titles and abstracts against a set of pre-defined eligibility criteria. Only one reviewer was involved in this round of review and the criteria was relative wide. If any uncertainty on inclusion existed, a second reviewer would join to assess and reach a consensus. Then, the full texts of retained references after first-round screening were obtained and reviewed by two reviewers against stringent inclusion criteria. Disagreements were resolved through discussion, and consensus was reached through a third party. All papers included after completion of the full text review were retained for data extraction and quality assessment.

## Data extraction and quality assessment

The following information was extracted from the eligible studies: first author, publication year, country of origin, setting, sample size, gender distribution, mean ages, mortality rate, test methods, and diagnostic performances (AUC, cut-off value, sensitivity, and specificity).

Two investigators independently assessed the quality of eligible studies using the revised Quality Assessment for Studies of Diagnostic Accuracy tool (QUADAS-2).<sup>9</sup> Agreement between the two reviewers for assessment of methodological quality was evaluated using the Cohen's Kappa statistic. Any disagreement in data extraction and quality assessment was resolved by discussion.

## Statistical analysis

The analyses were performed with Review Manager (REVMAN) 5.3 Copenhagen (The Nordic Cochrane Centre, The Cochrane Collaboration, 2014) and STATA (version 14; Stata Corp., College Station, Texas, USA). Reported values are 2-tailed, and hypothesis-testing results were considered statistically significant at  $P < 0.05$ .

Relative risk (RR) was used to assess the predictive value of ADM and proADM for mortality. We tested heterogeneity with Cochran's  $Q$  statistic, with  $P < 0.10$  indicating heterogeneity, and quantified the degree of heterogeneity using the  $I^2$  and  $\tau^2$  statistic. In case of significant heterogeneity between studies, DerSimonian and Laird random effects model was used; otherwise, the fixed effects model was performed.<sup>10</sup> Publication bias was tested using Deek's funnel plot.

The presence of a threshold effect on the prognostic accuracy of ADM and proADM in patients with sepsis was evaluated with the Spearman correlation coefficient between the logits of sensitivity and specificity. If no threshold effect existed, a bivariate random effects regression model<sup>11</sup> was used to calculate the pooled sensitivity, specificity, diagnostic odds ratio (DOR), positive likelihood ratio (PLR), and negative likelihood ratio (NLR). We also constructed a summary receiver operator characteristic (SROC) curve by plotting the individual and summary points of sensitivity and specificity to assess the overall diagnostic accuracy.<sup>12</sup>

## Results

### Literature search and study characteristics

Eventually, 13 articles were eventually included after examining the initial searched 279 articles. The process of study selection and the final results of the search were illustrated in the Flow Diagram (Fig. 1).

Thirteen studies involving 2556 patients were published from 1999 to 2017.<sup>13-25</sup> Five studies reported the prognostic values of ADM and eight reported the proADM (Table 1). All studies were published in English. The mean age of patients varied between 60.0 and 72.0 years and the proportion of men ranged from 58.6% to 74.2%. Eight studies were performed in ICUs, two in EDs and three in both departments. Follow-up periods differed across studies, including 28-days mortality (5 studies), 90-days mortality (1 study), and in-hospital mortality (7 studies). The mortality rate varied from 23.5% to 47.6%.

### Quality assessment

Fig. 2 summarizes the methodological quality assessment with the QUADAS-2 tool of the thirteen included studies. Three studies were labeled as unclear in the patient selection domain as there is no report on whether patients were consecutive (Fig. 2A). For the index text domain, there is





Figure 1 Flowchart of study selection.

**Table 1** Characteristics of included studies.

	Author	Year	Country	Setting	N	Age	Male (%)	Outcomes	Mortality rate	Cutoff value (nmol/l)	SEN (%)	SPE (%)
ADM	Ueda <sup>13</sup>	1999	Japan	ED/ICU	46	60.0 ± 3.8	35 (76.1%)	28-Day mortality	28.3%	0.15	65.0	92
	Chen <sup>14</sup>	2013	China	ED	684	72 (56–78)	419 (61.3%)	In-hospital mortality	34.7%	34.49 ng/l	81.6	60.8
	Marino <sup>15</sup>	2014	Italy	ED	101	78 (72–83)	61 (60.4%)	28-Day mortality	28.7%	–	–	–
	Caironi <sup>16</sup>	2017	Italy	ICU	956	71	561 (58.7%)	90-Day mortality	38.6%	–	–	–
	Charles <sup>17</sup>	2017	France	ICU	237	67.8 ± 13.7	110 (63.6%)	28-Day mortality	36.4%	5.19	–	–
ProADM	Christ-Crain <sup>18</sup>	2005	Switzerland	ICU	53	–	–	In-hospital mortality	23.5%	3.9	83.3	87.8
	Guignant <sup>19</sup>	2009	France	ICU	99	67 (54–76)	58 (58.6%)	28-Day mortality	35.0%	4	78.0	83.0
	Wang <sup>20</sup>	2010	China	ICU	26	–	–	In-hospital mortality	30.8%	0.8 ng/ml	91.0	73.0
	Suberviola <sup>21</sup>	2012	Spain	ICU	49	59.4 ± 13.4	33 (67.3%)	In-hospital mortality	34.7%	4.86	53.0	84.0
	Suberviola <sup>22</sup>	2013	Spain	ED/ICU	137	62.6 ± 15.9	90 (65.7%)	In-hospital mortality	29.9%	4.87	61.0	67.7
	Pezzilli <sup>23</sup>	2012	Italy	ICU	21	69 (41–85)	13 (61.9%)	In-hospital mortality	47.6%	1.64	71.4	72.7
	Akpinar <sup>24</sup>	2014	Turkey	ICU	31	61.8 ± 17.2	23 (74.2%)	In-hospital mortality	–	–	24.0	90.3
Ara-Somohano <sup>25</sup>	2017	France	ED/ICU	116	72.0 ± 14.8	–	28-Day mortality	31.0%	2.143	79.4	68.3	

ADM: adrenomedullin; proADM: proadrenomedullin; ICU: intensive care unit; ED: emergency department; SEN: sensitivity; SPE: specificity.




**Figure 2** Quality assessment (QUADAS-2) summary of 13 studies (A) and quality assessment (QUADAS-2) for each included study (B).

no cutoff value in three studies which has been labeled as unclear. The reference standard domain of two studies were labeled as high risk as the ADM or proADM levels were calculated before the endpoint was revealed. Seven studies were labeled as unclear because whether ADM or proADM were measured in a blinded fashion is unknown. There is neither risk in flow timing nor application concerns in all these thirteen studies (Fig. 2B). The Cohen's Kappa statistic for inter-rater agreement of assessment of quality between two reviewers was 0.84.

### Association of ADM and proADM with mortality

All studies showed that an elevated ADM or proADM levels were associated with a higher risk of death, with RR ranging

from 1.58 to 12.67. Due to the substantial heterogeneity between studies ( $I^2 = 82\%$ ,  $Tau^2 = 0.30$ , Cochran's  $Q$  statistic  $P < 0.01$ ), a random-effects model was used to pool RR estimates (Fig. 3). The pooled RR in all the 13 studies was 3.31 (95%CI, 2.31–4.75). Subgroup analyses indicated the pooled RRs were 3.12 (95%CI, 1.75–5.56) and 3.43 (95%CI, 2.21–5.31) for ADM and proADM, respectively. To explore the source of between-study heterogeneity, further analyses was performed (data not shown), showing that the pooled RRs comparing high with low level of proADM were 2.96 (95%CI, 2.12–4.13) for in-hospital mortality and 5.21 (95%CI, 3.10–8.77) for 28-day mortality. The definition of cutoff value may also bring about heterogeneity as the pooled RRs were 3.18 (95%CI, 2.21–4.56) for high cutoff value ( $\geq 4$  nmol/l) and 5.43 (95%CI, 3.13–9.40) for low cutoff value ( $< 4$  nmol/l).



**Figure 3** Forest plot of ADM or proADM to predict mortality in sepsis.

## Diagnostic accuracy of ADM and proADM for mortality

There is no statistically significant difference when exploring for threshold effect (Spearman correlation coefficient = 0.071;  $P = 0.74$ ). Totally ten studies were included for assessing the diagnostic accuracy of ADM and proADM for mortality in patients with sepsis. As shown in Fig. 4, the pooled sensitivity and specificity of included 10 studies were 0.72 (95%CI, 0.64–0.78) and 0.77 (95%CI, 0.69–0.83), respectively. The PLR and NLR were 3.1 (95%CI, 2.3–4.1) and 0.37 (95%CI, 0.29–0.47), respectively (data not shown). The DOR was 8.11 (95%CI, 5.25–12.54) (data not shown). The overall area under the SROC curve was 0.80 (95%CI, 0.77–0.84) (Fig. 5).

## Publication bias

The Deek's funnel plot of the included studies showed that publication bias was not statistically significant ( $P = 0.24$ ) (Fig. 6).

## Discussion

Early prognosis and risk assessment after sepsis may provide timely and accurate treatment for patients. Since it is dominated by major peripheral vasodilation and other cardiovascular system alternations during the first hours after the onset of sepsis or septic shock,<sup>26</sup> the measurement of the biomarkers including vasodilator and vasoconstrictor may be

of great interest as they play vital roles in the homeostasis of the system. Our present systematic review and meta-analysis involving 13 high-quality clinical studies illustrates that both ADM and proADM are positively associated with the mortality risk for patients with sepsis.

Studies conducted by Chen et al.<sup>14</sup> and Akpinar et al.<sup>24</sup> show that ADM and proADM levels in survivors are significantly lower than those in non-survivors in patients with systemic inflammatory response syndrome (SIRS), sepsis, severe sepsis and septic shock. Moreover, ADM is regarded as an independent predictor of in-hospital mortality for sepsis in the multivariate logistic regressions.<sup>14,19</sup> A similar positive association of proADM with short-term mortality in patients with community-acquired pneumonia (CAP) has been reported in a prior meta-analysis by Cavallazzi et al.<sup>27</sup>

The pooled sensitivity and specificity in this study were optimal, reaching 0.72 and 0.77, respectively. Generally, there is a trade-off between sensitivity and specificity in a test of diagnostic accuracy. That is, an increase in sensitivity (the true positive rate) is usually accompanied by a reduction in specificity (the true negative rate). Thus, the AUC should be a comprehensive index. The present study found that the AUC for sROC was 0.80 (95%CI, 0.77–0.84), which was greater than the results of published meta-analyses of procalcitonin,<sup>28</sup> troponins<sup>29</sup> and lactate clearance.<sup>30</sup> A study reported by Ara-Somohano evaluated eight biomarkers (ProADM, proANP, pro-endothelin, copeptin, amino-terminal pro-B-type Natriuretic Peptide, troponin, C-reactive protein, procalcitonin) to predict short-term mortality in patients with sepsis, among which ProADM (AUC = 0.731; 95%CI: 0.658–0.804) presented the best




Figure 4 Sensitivity and specificity of ADM or proADM for the predicting of mortality in patients with sepsis.




Figure 5 Summary receiver operating characteristic of ADM or proADM for the predicting of mortality in patients with sepsis.




Figure 6 Deek's funnel plot asymmetry test for publication bias.

accuracy. All the results revealed that ADM and proADM should be a strong predictor for sepsis mortality.

In view of the complexity of the sepsis response, a great number of researchers have attempted to combine the

comprehensive but subjective and time-consuming severity scoring systems with biomarkers. The prognostic ability of the combination of ADM with Mortality in Emergency Department Sepsis (MEDS) score was superior to either ADM or MEDS score alone.<sup>14</sup> In addition, the combination of Sequential Organ Failure Assessment (SOFA), Acute Physiological and Chronic Health Evaluation (APACHE) II scores, and MR-proADM was efficient to predict prognosis and mortality rate in severe sepsis or septic shock patients.<sup>24</sup> These data

indicate that combined use of severity scoring systems and biomarkers is more effective in risk stratification and prognosis.

Flaws in the design of these studies should be considered when interpreting the results of the present systematic review and meta-analysis. It is sometimes not clear how the investigators selected the subjects (consecutively, randomly, or neither).<sup>13,16,24</sup> If the subjects were not recruited either consecutively or randomly, this may introduce selection bias. The thresholds used in the studies were not always pre-specified, which may also introduce bias.<sup>15,16,24</sup> In addition, a limitation inherent to the meta-analysis is the potential heterogeneity among studies that might lead to inaccurate conclusions. This may relate to the fact that the definition of mortality and cutoff values were inconsistent across the trials. Moreover, most studies included in this meta-analysis are performed prior to the publication of the updated definitions and clinical criteria of sepsis and septic shock (SPESIS-3),<sup>31</sup> which may cause a potential limitation on the reproducibility of the results.

## Conclusion

The present systematic review indicates that ADM and proADM are effective biomarkers for the prediction of mortality risk in patients with sepsis. Further systematic reviews need to be performed to assess the accuracy of combination of ADM/proADM with severity scoring systems or other biomarkers.

## Contributions

All authors have approved the final article. QL, BW, LY, CP, LM and CC design the experiment, collect data and write this article; QL and BW perform the analysis.

## Conflict of interest

The authors declare no conflict of interest.

## Acknowledgement

The study was supported by Science and Technology Plan Project of Chengguan District of Lanzhou (No. 2016-7-17).

## References

- Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. *N Engl J Med*. 2003;348:1546–54.
- Rhee C, Dantes R, Epstein L, Murphy DJ, Seymour CW, Iwashyna TJ, et al. Incidence and Trends of Sepsis in US Hospitals Using Clinical vs Claims Data, 2009–2014. *JAMA*. 2017;318:1241–9.
- Chen KF, Chaou CH, Jiang JY, Yu HW, Meng YH, Tang WC, et al. Diagnostic accuracy of lipopolysaccharide-binding protein as biomarker for sepsis in adult patients: a systematic review and meta-analysis. *PLOS ONE*. 2016;11:e0153188, <http://dx.doi.org/10.1371/journal.pone.0153188>.
- Kitamura K, Kangawa K, Kawamoto M, Ichiki Y, Nakamura S, Matsuo H, et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. *Biochem Biophys Res Commun*. 1993;192:553–60.
- Hirata Y, Mitaka C, Sato K, Nagura T, Tsunoda Y, Amaha K, et al. Increased circulating adrenomedullin, a novel vasodilatory peptide, in sepsis. *J Clin Endocrinol Metab*. 1996;81:1449–53.
- Nishio K, Akai Y, Murao Y, Doi N, Ueda S, Tabuse H, et al. Increased plasma concentrations of adrenomedullin correlate with relaxation of vascular tone in patients with septic shock. *Crit Care Med*. 1997;25:953–7.
- Struck J, Tao C, Morgenthaler NG, Bergmann A. Identification of an Adrenomedullin precursor fragment in plasma of sepsis patients. *Peptides*. 2004;25:1369–72.
- Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ*. 2009;339:b2535.
- Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. *BMC Med Res Methodol*. 2003;3:25.
- Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ*. 2003;327:557–60.
- Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. *J Clin Epidemiol*. 2005;58:982–90.
- Moses LE, Shapiro D, Littenberg B. Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. *Stat Med*. 1993;12:1293–316.
- Ueda S, Nishio K, Minamino N, Kubo A, Akai Y, Kangawa K, et al. Increased plasma levels of adrenomedullin in patients with systemic inflammatory response syndrome. *Am J Respir Crit Care Med*. 1999;160:132–6.
- Chen YX, Li CS. Prognostic value of adrenomedullin in septic patients in the ED. *Am J Emerg Med*. 2013;31:1017–21.
- Marino R, Struck J, Maisel AS, Magrini L, Bergmann A, Di Somma S. Plasma adrenomedullin is associated with short-term mortality and vasopressor requirement in patients admitted with sepsis. *Crit Care*. 2014;18:R34.
- Caironi P, Latini R, Struck J, Hartmann O, Bergmann A, Maggio G, et al. Circulating biologically active adrenomedullin (bio-ADM) predicts hemodynamic support requirement and mortality during sepsis. *Chest*. 2017;152:312–20.
- Charles PE, Peju E, Dantec A, Bruyere R, Meunier-Beillard N, Dargent A, et al. MR-ProADM elevation upon ICU admission predicts the outcome of septic patients and is correlated with upcoming fluid overload. *Shock*. 2017;48:418–26.
- Christ-Crain M, Morgenthaler NG, Struck J, Harbarth S, Bergmann A, Muller B. Mid-regional pro-adrenomedullin as a prognostic marker in sepsis: an observational study. *Crit Care*. 2005;9:R816–24.
- Guignant C, Voirin N, Venet F, Poitevin F, Malcus C, Bohe J, et al. Assessment of pro-vasopressin and pro-adrenomedullin as predictors of 28-day mortality in septic shock patients. *Intensive Care Med*. 2009;35:1859–67.
- Wang RL, Kang FX. Prediction about severity and outcome of sepsis by pro-atrial natriuretic peptide and pro-adrenomedullin. *Chin J Traumatol*. 2010;13:152–7.
- Suberviola B, Castellanos-Ortega A, Llorca J, Ortiz F, Iglesias D, Prieto B. Prognostic value of proadrenomedullin in severe sepsis and septic shock patients with community-acquired pneumonia. *Swiss Med Wkly*. 2012;142:w13542.
- Suberviola B, Castellanos-Ortega A, Ruiz Ruiz A, Lopez-Hoyos M, Santibanez M. Hospital mortality prognostication in sepsis using the new biomarkers suPAR and proADM in a single determination on ICU admission. *Intensive Care Med*. 2013;39:1945–52.
- Pezzilli R, Barassi A, Pigna A, Morselli-Labate AM, Imbrogno A, Fabbri D, et al. Time course of proadrenomedullin in the early

- phase of septic shock. A comparative study with other proinflammatory proteins. *Panminerva Med.* 2012;54:211–7.
24. Akpinar S, Rollas K, Alagoz A, Segmen F, Sipit T. Performance evaluation of MR-proadrenomedullin and other scoring systems in severe sepsis with pneumonia. *J Thorac Dis.* 2014;6:921–9.
  25. Ara-Somohano C, Bonadona A, Carpentier F, Pavese P, Vesin A, Hamidfar-Roy R, et al. Evaluation of eight biomarkers to predict short-term mortality in patients with acute severe dyspnea. *Minerva Anesthesiol.* 2017;83:824–35.
  26. Hollenberg SM, Ahrens TS, Annane D, Astiz ME, Chalfin DB, Dasta JF, et al. Practice parameters for hemodynamic support of sepsis in adult patients: 2004 update. *Crit Care Med.* 2004;32:1928–48.
  27. Cavallazzi R, El-Kersh K, Abu-Atherah E, Singh S, Loke YK, Wiemken T, et al. Midregional proadrenomedullin for prognosis in community-acquired pneumonia: a systematic review. *Respir Med.* 2014;108:1569–80.
  28. Liu D, Su L, Han G, Yan P, Xie L. Prognostic value of procalcitonin in adult patients with sepsis: a systematic review and meta-analysis. *PLOS ONE.* 2015;10:e0129450, <http://dx.doi.org/10.1371/journal.pone.0129450>.
  29. Bessiere F, Khenifer S, Dubourg J, Durieu I, Lega JC. Prognostic value of troponins in sepsis: a meta-analysis. *Intensive Care Med.* 2013;39:1181–9.
  30. Zhang Z, Xu X, Chen K. Lactate clearance as a useful biomarker for the prediction of all-cause mortality in critically ill patients: a systematic review study protocol. *BMJ Open.* 2014;4:e004752, <http://dx.doi.org/10.1136/bmjopen-2013-004752>.
  31. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA.* 2016;315:801–10.